In accordance with NSCLC, the results showed that the reduction in HCC markers, including AFP and PIVKA-II, can also predict the efficiency of anti-PD-1 therapy and the prognosis of HCC patients. The gene discussed is AFP; the disease is hepatocellular carcinoma.